Osimertinib
Generic name: Osimertinib
Brand names: Tagrisso
Dosage form: oral tablet (40 mg; 80 mg)
Drug class:
EGFR inhibitors
Usage of Osimertinib
Osimertinib is used to treat non-small cell lung cancer that is positive for an abnormal "EGFR" gene. You doctor will test you for this gene.
Osimertinib is sometimes given when the cancer has spread to other parts of the body (metastatic), or may come back after surgery.
Osimertinib may also be used for purposes not listed in this medication guide.
Osimertinib side effects
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Osimertinib may cause serious side effects. Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects of osimertinib may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Osimertinib
You should not use osimertinib if you are allergic to it.
Tell your doctor if you have ever had:
Osimertinib can harm an unborn baby if the mother or the father is using osimertinib.
Pregnancy may be less likely to occur while the mother or the father is using this medicine. Both men and women should still use birth control to prevent pregnancy because the medicine can harm an unborn baby.
Do not breastfeed while using this medicine, and for at least 2 weeks after your last dose.
Relate drugs
- Cetuximab
- Erbitux
- Erlotinib
- Exkivity
- Gefitinib
- Iressa
- Mobocertinib
- Necitumumab
- Osimertinib
- Panitumumab
- Portrazza
- Tagrisso
- Tarceva
- Vectibix
How to use Osimertinib
Usual Adult Dose for Non-Small Cell Lung Cancer:
80 mg orally once a day Duration of therapy:-Adjuvant setting: Until disease progression, unacceptable toxicity, or for up to 3 yearsMetastatic lung cancer: Until disease progression or unacceptable toxicityUses: -As adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test-For first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test-For treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy
Warnings
Osimertinib can cause serious side effects on your heart, lungs, skin, or eyes.
Call your doctor at once if you have fast or pounding heartbeats, swelling in your lower legs, fever, cough, trouble breathing, skin blistering or peeling, vision changes, eye pain, increased sensitivity to light, or if you feel light-headed or short of breath.
What other drugs will affect Osimertinib
Osimertinib can cause a serious heart problem. Your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV.
Other drugs may affect osimertinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions